Literature DB >> 27044826

The protective effects of bone marrow-derived mesenchymal stem cell (BMSC) on LPS-induced acute lung injury via TLR3-mediated IFNs, MAPK and NF-κB signaling pathways.

Jingcai Wang1, Ying Qin2, Xiuju Mi1.   

Abstract

The study attempted to clarify the protective role of bone marrow-derived mesenchymal stem cell (BMSC) transplantation on LPS-induced acute lung injury (ALI) of rats. BMSC were obtained from bone marrow of rat, cultured and proliferated in vitro. Rats of ALI were established through lipopolysaccharide (LPS) administration. Male rats were allocated to control group, ALI group and BMSC, transplantation group. Rats were sacrificed after BMSC injection after 12h, 24h and 48h. Here we investigated the role of BMSC in LPS-induced alveolar macrophages to further demonstrate the mechanism of BMSC to lung injury. TLR3, a member of Toll-like receptor family, has been found in macrophages and the cell surface. In our study, first BMSC successfully reversed LPS-induced lung injury by hematoxylin-eosin (H&E) staining, ameliorated apoptosis via TUNEL and flow cytometer analysis, as well as improved cell structure. And then, western blot, quantitative real-time PCR, immunohistochemistry and immunofluorescence analysis were used to confirm that TLR3 was significantly down-regulated for BMSC treatment. Subsequently, TRIF and RIP1, down-streaming signals of TLR3, were inhibited greatly, leading to TRAF3, MAPK as well as NF-κB inactivity. Our results indicated that BMSC transplantation group displayed inhibitory effects on interferon (IFNs) levels via TLR3 in LPS-induced ALI and preventive effects on inflammation response via TLR3-regualted MAPK and NF-κB signaling pathway in LPS-induced lung injury. The present study indicated that BMSC could display protective effects on LPS-induced ALI and provide an experimental basis for clinical therapy.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acute lung injury; BMSC; Inflammation; LPS; TLR3

Mesh:

Substances:

Year:  2016        PMID: 27044826     DOI: 10.1016/j.biopha.2016.02.037

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Dexmedetomidine mitigates CLP-stimulated acute lung injury via restraining the RAGE pathway.

Authors:  Hongyi Hu; Dongsheng Shi; Chenlu Hu; Xiao Yuan; Juan Zhang; Huaqin Sun
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 2.  Modulation of cell signaling pathways by Phyllanthus amarus and its major constituents: potential role in the prevention and treatment of inflammation and cancer.

Authors:  Hemavathy Harikrishnan; Ibrahim Jantan; Akilandeshwari Alagan; Md Areeful Haque
Journal:  Inflammopharmacology       Date:  2019-12-02       Impact factor: 4.473

3.  MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction.

Authors:  Yueqiu Chen; Yunfeng Zhao; Weiqian Chen; Lincen Xie; Zhen-Ao Zhao; Junjie Yang; Yihuan Chen; Wei Lei; Zhenya Shen
Journal:  Stem Cell Res Ther       Date:  2017-11-25       Impact factor: 6.832

4.  MicroRNA-17-5p aggravates lipopolysaccharide-induced injury in nasal epithelial cells by targeting Smad7.

Authors:  Nan Huang; Wenjing Li; Xiaolong Wang; Shanshan Qi
Journal:  BMC Cell Biol       Date:  2018-02-13       Impact factor: 4.241

5.  PDK2 promotes chondrogenic differentiation of mesenchymal stem cells by upregulation of Sox6 and activation of JNK/MAPK/ERK pathway.

Authors:  H Wang; X B Shan; Y J Qiao
Journal:  Braz J Med Biol Res       Date:  2017-02-16       Impact factor: 2.590

6.  Ugonin M, a Helminthostachys zeylanica Constituent, Prevents LPS-Induced Acute Lung Injury through TLR4-Mediated MAPK and NF-κB Signaling Pathways.

Authors:  Kun-Chang Wu; Shyh-Shyun Huang; Yueh-Hsiung Kuo; Yu-Ling Ho; Chang-Syun Yang; Yuan-Shiun Chang; Guan-Jhong Huang
Journal:  Molecules       Date:  2017-04-01       Impact factor: 4.411

7.  Toxic proteins from Croton tiglium L. exert a proinflammatory effect by inducing release of proinflammatory cytokines and activating the p38-MAPK signaling pathway.

Authors:  Liping Liu; Hongli Yu; Hao Wu; Xiaolin Yang; Yaozong Pan; Yeqing Chen; Kuilong Wang; Wei Wang; Wenying Zhang; Yangping Jin; Chengchao Zhang; Ai Jiang; Chunyan Xia
Journal:  Mol Med Rep       Date:  2017-05-24       Impact factor: 2.952

8.  Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression.

Authors:  Xiaoning Zhang; Zhiqiang Zhang; Mingyan Ju; Jiaci Li; Yaqing Jing; Yuxia Zhao; Chao Gu; Ming Dong; Guang Li; Yi Liu
Journal:  Inflammopharmacology       Date:  2020-03-13       Impact factor: 4.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.